A Phase I/IIa Study of EF-009 in Patients with Pancreatic Cancer

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2026

Conditions
Pancreatic Cancer
Interventions
DRUG

EF-009

"Subjects who meet the eligibility criteria will have completed following evaluations and assessments before receiving treatment: a) review of medical and medication history; b) physical examination, vital signs and documentation of ECOG; c) ECG; d) routine serum biochemical, hematologic, urine pregnancy (if applicable) and urine laboratory assessments; and e) evaluation of European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 score.~On Day 0, subjects will undergo EF-009 wafer implantation via laparoscopy"

All Listed Sponsors
lead

Everfront Biotech Co., Ltd.

INDUSTRY